Covid-19 roundup: No­vavax vac­cine au­tho­rized in EU for teens; CEPI backs Co­di­ak's ef­forts on be­ta­coro­n­avirus shot

Sev­en months af­ter the Eu­ro­pean Com­mis­sion grant­ed con­di­tion­al ap­proval to No­vavax’s Covid-19 vac­cine Nu­vax­ovid in adults, the biotech is back with a new Eu­ro­pean au­tho­riza­tion.

No­vavax an­nounced Tues­day that the EC ap­proved ex­pand­ing the vac­cine’s con­di­tion­al mar­ket­ing au­tho­riza­tion to in­clude ado­les­cents ages 12-17. The biotech got a pos­i­tive CHMP opin­ion on us­ing the vac­cine in that age group al­most two weeks ago.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER